(1888PressRelease)
January 23, 2008 - Dr. Reddy’s has launched Supanac ® (Diclofenac potassium immediate release 50 mg tablets) in India, increasing its offering in the Rs 2700 crores (~ $688 million) NSAID market. (Source: IMS ORG June MAT ’07).
Supanac ® is in-licensed from Applied Pharma Research (APR), Switzerland and is used for Acute Pain management. This patented product has been developed by Dynamic Buffered Technology (DBT) making it a superior formulation of Diclofenac, which reaches peak plasma concentration approximately four times faster than Diclofenac enteric coated preparations thereby ensuring faster pain relief
The NSAID market size is about Rs 2700 crores (~ $688 million) (Source: IMS ORG June MAT ’07), growing at the rate of 20%.
Diclofenac comes under the category of NSAIDs (Non-steroidal Anti-inflammatory drugs).It has been marketed in India for more than 15 years and it is widely used for pain management.
Supanac® is available in strips of 10 tablets each.
Leading brands of Dr. Reddy’s in this segment are Nise and Retoz
Brief mode of action of Supanac:
Supanac® is a Non-steroidal anti-inflammatory (NSAID) drug that exhibits analgesic, anti-pyretic and anti-inflammatory activities
Supanac® as other NSAIDs; acts by prostaglandin synthetase inhibition.
About Dr. Reddy’s:
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer. ( www.drreddys.com )
Contact Information:
Investor Relations:
Nikhil Shah at nikhilshah ( @ ) drreddys dot com or on +91-40-23731946 ext dot 308
Media:
M Mythili at mythilim ( @ ) drreddys dot com or on +91-40-66511620
###
